Houston-area researchers are innovating health and wellness solutions every day — even focusing on non-pandemic-related issues. Getty Images

Researchers across the world are coming up with innovative breakthroughs regarding the coronavirus, but Houston research institutions are also making health and wellness discoveries outside of COVID-19.

Here are three from Houston researchers from a muscular atrophy study from outer space to a research project that might allow blind patients to "see."

Houston Methodist's research on muscular atrophy in astronauts

Scientists are studying the effect of certain drugs to help preserve muscles in astronauts. Photo courtesy of Houston Methodist/Facebook

Houston Methodist researcher Alessandro Grattoni and his team published research on muscular atrophy in astronauts. The research was published in Advanced Therapeutics and focused on his 2017 RR-6 muscle atrophy study that was conducted on the International Space Station.

While the current standard practice for astronauts maintaining their muscles is working out over two hours a day, the research found that use of drugs could also help preserve muscles. On a SpaceX refuel mission, mice that were implanted with a "Nanofluidic Delivery System" were sent up to space and monitored, according to a report. The device gradually released small doses of formoterol, an FDA approved drug for use in bronchodilation that has also been shown to stimulate increased muscle mass.

University of Houston researcher tracking fear response to improve mental health treatment

The research could help advance wearable devices. Photo via uh.edu

University of Houston researchers are looking into the way the body responds to fear in order to enhance mental health treatment. Rose Faghih, assistant professor of electrical and computer engineering, and doctoral student Dilranjan Wickramasuriya in the Computational Medicine Lab (CML) are leading the project.

"We developed a mixed filter algorithm to continuously track a person's level of sympathetic nervous system activation using skin conductance and heart rate measurements," writes Faghih in the journal PLOS One. "This level of sympathetic activation is closely tied to what is known as emotional arousal or sympathetic arousal."

When this sympathetic nervous system is activated — sometimes known as the "fight or flight" response — the heart beats faster and more oxygen is delivered to the muscles, according to a press release. Then, the body begins to sweat in order to cool down.

"Using measurements of the variations in the conductivity of the skin and the rate at which the heart beats, and by developing mathematical models that govern these relationships, CML researchers have illustrated that the sympathetic nervous system's activation level can be tracked continuously," reports Faghih.

This algorithm could be used in a wearable electronic device that could be worn by a patient diagnosed with a fear or anxiety disorder.

Baylor College of Medicine's vision-restoring research

What if a device could see for you? Photo from Pexels

When someone loses their vision, it's likely due to damage to the eyes or optic nerve. However, the brain that interprets what they eyes sees, works perfectly fine. But researchers from Baylor College of Medicine have worked on a thesis that a device with a camera could be designed and implemented to do the seeing for the blind patient.

"When we used electrical stimulation to dynamically trace letters directly on patients' brains, they were able to 'see' the intended letter shapes and could correctly identify different letters," says Dr. Daniel Yoshor, professor and chair of neurosurgery in a press release. "They described seeing glowing spots or lines forming the letters, like skywriting."

Through a study supported by the National Eye Institute with both sighted and blind people using implanted devices, the investigators determined that the process was promising. According to the release, the researchers identified several obstacles must be overcome before this technology could be implemented in clinical practice.

"The primary visual cortex, where the electrodes were implanted, contains half a billion neurons. In this study we stimulated only a small fraction of these neurons with a handful of electrodes," says said Dr. Michael Beauchamp, professor and in neurosurgery, in the release.

"An important next step will be to work with neuroengineers to develop electrode arrays with thousands of electrodes, allowing us to stimulate more precisely. Together with new hardware, improved stimulation algorithms will help realize the dream of delivering useful visual information to blind people."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston investor on SaaS investing and cracking product-market fit

Houston innovators podcast episode 230

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption."

An example of this type of company is Houston-based RepeatMD, which raised a $50 million series A round last November. Mercury's Fund V, which closed at an oversubscribed $160 million, contributed to RepeatMD's round.

"While looking at that investment, it really made me re-calibrate a lot of my thoughts in terms what product-market fit meant," Gilani says. "At RepeatMD, we had customers that were so eager for the service that they were literally buying into products while we were still making them."

Gilani says he's focused on finding more of these high-growth companies to add to Mercury's portfolio amidst what, admittedly, has been a tough time for venture capital. But 2024 has been looking better for those fundraising.

"We've some potential for improvement," Gilani says. "But overall, the environment is constrained, interest rates haven't budged, and we've seen some potential for IPO activity."

Gilani shares more insight into his investment thesis, what areas of tech he's been focused on recently, and how Houston has developed as an ecosystem on the podcast.

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

Houston researcher scores prestigious NSF award for machine learning, power grid tech

grant funding

An associate professor at the University of Houston received the highly competitive National Science Foundation CAREER Award earlier this month for a proposal focused on integrating renewable resources to improve power grids.

The award grants more than $500,000 to Xingpeng Li, assistant professor of electrical and computer engineering and leader of the Renewable Power Grid Lab at UH, to continue his work on developing ways to use machine learning to ensure that power systems can continue to run efficiently when pulling their energy from wind and solar sources, according to a statement from UH. This work has applications in the events of large disturbances to the grid.

Li explains that currently, power grids run off of converted, stored kinetic energy during grid disturbances.

"For example, when the grid experiences sudden large generation losses or increased electrical loads, the stored kinetic energy immediately converted to electrical energy and addressed the temporary shortfall in generation,” Li said in a statement. “However, as the proportion of wind and solar power increases in the grid, we want to maximize their use since their marginal costs are zero and they provide clean energy. Since we reduce the use of those traditional generators, we also reduce the power system inertia (or stored kinetic energy) substantially.”

Li plans to use machine learning to create more streamlined models that can be implemented into day-ahead scheduling applications that grid operators currently use.

“With the proposed new modeling and computational approaches, we can better manage grids and ensure it can supply continuous quality power to all the consumers," he said.

In addition to supporting Li's research and model creations, the funds will also go toward Li and his team's creation of a free, open-source tool for students from kindergarten up through their graduate studies. They are also developing an “Applied Machine Learning in Power Systems” course. Li says the course will help meet workforce needs.

The CAREER Award recognizes early-career faculty members who “have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization,” according to the NSF. It's given to about 500 researchers each year.

Earlier this year, Rice assistant professor Amanda Marciel was also

granted an NSF CAREER Award to continue her research in designing branch elastomers that return to their original shape after being stretched. The research has applications in stretchable electronics and biomimetic tissues.

------

This article originally ran on EnergyCapital.